-
Zindoxifene (INN;
former developmental code
names D-16726, NSC-341952) is a
nonsteroidal selective estrogen receptor modulator (SERM) that was
under development...
- that
includes zindoxifene, bazedoxifene, and pipendoxifene, as well as the
nonsteroidal estrogen D-15414 (the
major metabolite of
zindoxifene).
Michael Oettel;...
- (CI-628), NNC 45-0095, panomifene,
pipendoxifene (ERA-923), trioxifene, and
zindoxifene (D-16726).
Sivifene (A-007) was
initially thought to be a SERM due to...
- TAS-108 (SR-16234)
Toremifene Trioxifene TZE-5323 U-11555A U-11634 Y-134
Zindoxifene Zuclomifene Antagonists (R,R)-THC 7β-Hydroxy-DHEA
Chloroindazole Cytestrol...
- of the 2-phenylindole
group of
SERMs and is
structurally related to
zindoxifene and the
marketed bazedoxifene. The drug
reached phase II
clinical trials...
- TAS-108 (SR-16234)
Toremifene Trioxifene TZE-5323 U-11555A U-11634 Y-134
Zindoxifene Zuclomifene Antagonists (R,R)-THC 7β-Hydroxy-DHEA
Chloroindazole Cytestrol...
- The drug is a
member of the 2-phenylindole
group of SERMs,
along with
zindoxifene and pipendoxifene. The drug was
approved in the
European Union by the...
- TAS-108 (SR-16234)
Toremifene Trioxifene TZE-5323 U-11555A U-11634 Y-134
Zindoxifene Zuclomifene Antagonists (R,R)-THC 7β-Hydroxy-DHEA
Chloroindazole Cytestrol...
-
major metabolite of the
selective estrogen receptor modulator (SERM)
zindoxifene (D-16726). D-15414 has high
affinity for the
estrogen receptor (ER) and...
- TAS-108 (SR-16234)
Toremifene Trioxifene TZE-5323 U-11555A U-11634 Y-134
Zindoxifene Zuclomifene Antagonists (R,R)-THC 7β-Hydroxy-DHEA
Chloroindazole Cytestrol...
